Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration. - Wikidata - awgldk - TriplyDB

Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.

Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.

http://www.wikidata.org/entity/Q35925767

about

Mitochondria: A Therapeutic Target for Parkinson's Disease?Protein Kinases and Parkinson's Disease LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PREDIGT score G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?Early synaptic dysfunction in Parkinson's disease: Insights from animal models.Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases.Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Defects in trafficking bridge Parkinson's disease pathology and genetics.Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation.Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.LRRK2 and the Immune System.Targeting LRRK2 in Parkinson's disease: an update on recent developments.Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease.Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease.Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model.Novel gene (TMEM230) linked to Parkinson's disease.Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells.In vivo models of alpha-synuclein transmission and propagation.Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2.Mechanisms of Mutant LRRK2 Neurodegeneration.Lack of PINK1 alters glia innate immune responses and enhances inflammation-induced, nitric oxide-mediated neuron death.New developments in genetic rat models of Parkinson's disease.Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease.LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease.Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4 A new hypothesis for Parkinson's disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics

P2860

Q26784216-CE334DA2-7B86-40AB-B6EA-55CF04066369 Q28067636-8900A694-1B05-48AE-9819-8B5FC1CF27B7 Q28078899-276ABA28-5726-473B-B6C7-2706DC55FD1C Q29048624-559FA288-99DE-4171-B568-11944B18138B Q37096048-09CD577E-C8D5-4076-8AE6-3C50EDAEC321 Q37513500-D4EDC6C9-502B-4B09-93BE-177C681B613E Q38790881-A57A252D-CC6E-41D7-A719-5C2FDE45D46A Q38837604-B3FC4B59-BDAF-44A5-B6A6-A554EA2B57C2 Q38974101-11F5BB57-BAA7-46FF-9A08-EB2944F25BDF Q39002226-DA0419E0-6F46-49BD-8501-7896F00A7DCF Q39004335-4970818E-4436-4CAF-8855-86B20387944F Q39137358-EDC59755-CE21-4578-80BC-1F2EC83D44A6 Q39206431-D6E2B538-7B58-4442-BEA7-47E10522C5CA Q39206438-3509FA66-83CF-4E7B-BE23-054408749A39 Q39263032-9AA0D574-0294-4FE0-91E0-D8C3A29CB23E Q39289038-6AB2C575-F728-4277-9847-13C5911CF81F Q39392775-B60A1990-718F-45D1-8674-BC234EA7C164 Q41163700-E85D0D19-BEAF-4DA4-BBD8-F098AED06C71 Q41539639-B90040D8-2840-429E-81A5-10CB1A8923EF Q42368664-F0680CEA-99AF-47AB-B790-F7FDFA20163E Q42372493-006B04DB-22A1-46C8-91A9-180CFCF7F9F2 Q43137963-E093599E-F929-4BF7-9F29-F2EAB1B5076A Q46252300-68B94424-5EC8-46CD-84F7-5092CD3B7549 Q46520584-FA2BDA6B-9266-44EF-8FC7-A051C99071E9 Q47288069-933C742F-1792-4497-80A4-7EB6A989B3C4 Q48003270-80433BBD-9C33-4AD2-9875-5FA83D006FE1 Q48132251-DB9DA212-AE1E-4522-985D-B0A82C007917 Q48239635-B4597F73-49CA-4824-8488-1C4E2663E8E8 Q48267087-7F89DC2D-6F15-4C1F-BBA5-58CA989CC27D Q48502440-2E77779D-B7CE-43DF-A46D-CF5536929CC6 Q51082143-84FCD778-5F20-4170-8B51-55BE21CEA397 Q54972398-6CCF9EAA-C5CD-4725-955A-5E1093219E5A Q54977439-E30D6269-4E02-47A3-A7C8-09C6C6DC9B34 Q55240777-9D2AE7C6-F026-4368-843C-8FA0580F90D9 Q58111473-C0F6A9BF-2D34-4719-99E9-39F5FDC837B8 Q58803163-46C88B08-4D41-414C-8A62-054FEC7ECB8F

P2860

Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.

http://www.wikidata.org/entity/Q35925767

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Leucine-rich Repeat Kinase 2 ( ...... ene-induced Neurodegeneration.

@ast

Leucine-rich Repeat Kinase 2 ( ...... ene-induced Neurodegeneration.

@en

type

label

Leucine-rich Repeat Kinase 2 ( ...... ene-induced Neurodegeneration.

@ast

Leucine-rich Repeat Kinase 2 ( ...... ene-induced Neurodegeneration.

@en

prefLabel

Leucine-rich Repeat Kinase 2 ( ...... ene-induced Neurodegeneration.

@ast

Leucine-rich Repeat Kinase 2 ( ...... ene-induced Neurodegeneration.

@en

P1433

Q35925767-9ACFFF2F-0D8C-41A7-81DA-5C57DEBD2A78

P1476

Q35925767-3D9A38F8-6502-4E1A-BE41-725EC23A5A0E

P2093

Q35925767-2901DD93-413C-41E8-BC10-97403D87DCEA

Q35925767-70B3C506-34A7-45AC-A11B-908DB35F9301

Q35925767-78C73461-6CBE-4935-8B3A-2587F0EB0414

Q35925767-7AEADA3F-EAD8-47DD-8ACF-28E8140CF3CD

Q35925767-9DF9B6E0-59BB-4789-B72E-6F0FC018FD14

Q35925767-9EEB9560-841B-4DAD-A43F-11CA022F3329

Q35925767-9EEBCEB7-E270-427C-87A7-6044A7AC43E0

Q35925767-ACA02ACD-9F81-43EA-9B57-DA90427E412B

Q35925767-F28F86E2-8553-4023-B01F-851D2BBF93EC

Q35925767-F632D501-D62A-4D6B-B8E0-0586882A8FBD

P2860

Q35925767-0C793F2F-6D90-4D27-8F5E-12F2BB76FFDC

Q35925767-15FDFA7C-3AE5-44D0-93AA-4F1410D28552

Q35925767-19B2E42B-5679-4373-952B-13E29F2286AA

Q35925767-256BB9A4-A45F-485C-A8E8-2FF49F91BAFD

Q35925767-32A50BEF-1834-4FB8-A9D2-9BE16C49B21F

Q35925767-3E7EC675-8EA1-4397-B0C4-3060CE469AE2

Q35925767-408C86C2-39AD-42B3-90DC-5898C6FC1C78

Q35925767-448B0D9E-D443-4386-9D34-08111F1D5887

Q35925767-47F6862B-2877-4F60-A8AB-D77AAE88DE25

Q35925767-4A947D3E-1242-4DA4-8607-F6109F8C13CC

P304

Q35925767-8F8920E8-194A-446B-970F-ED366F6A3BF4

P31

Q35925767-279DE1EE-7B82-4B30-BB04-0AC027CE9E9E

P356

Q35925767-0E486B2A-120D-465B-B0B6-5C3104966E97

P407

Q35925767-93510782-B84B-4CEE-AE6D-0393857211CD

P433

Q35925767-F8FF3CB4-00DF-408B-AC11-E7F6B8835958

P478

Q35925767-F7B84B1F-4860-47BD-B49B-5986FA85BE0A

P50

Q35925767-29CCEBF6-8CE8-44F9-8ECF-0E6D8B6B69F7

Q35925767-620B1A6F-49BC-4B49-BAE8-C4D301207FB3

P577

Q35925767-46734144-9A7B-46D1-B347-3B58664C1362

P698

Q35925767-53DC7540-274B-44E2-BDC8-1A73747A8106

P921

Q35925767-C2C3B82F-73D1-457E-8988-450F0394BDCE

P932

Q35925767-1D614754-D42E-4A93-A137-B1FF1177D2B0

P356

JBC.M115.660001

P1433

Journal of Biological Chemistry

P1476

Leucine-rich Repeat Kinase 2 ( ...... ene-induced Neurodegeneration.

@en

P2093

Elie Needle

http://www.w3.org/2001/XMLSchema#string

Hisham A Abdelmotilib

http://www.w3.org/2001/XMLSchema#string

João P L Daher

http://www.w3.org/2001/XMLSchema#string

Kyle B Fraser

http://www.w3.org/2001/XMLSchema#string

Laura A Volpicelli-Daley

http://www.w3.org/2001/XMLSchema#string

Paul Galatsis

http://www.w3.org/2001/XMLSchema#string

Stefanus J Steyn

http://www.w3.org/2001/XMLSchema#string

Warren D Hirst

http://www.w3.org/2001/XMLSchema#string

Xianzhen Hu

http://www.w3.org/2001/XMLSchema#string

Yi Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

Kinase activity of mutant LRRK2 mediates neuronal toxicity

Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo

Interplay of LRRK2 with chaperone-mediated autophagy

Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons

Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic

High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain

Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis

Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor

alpha-Synuclein locus triplication causes Parkinson's disease

P304

19433-19444

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M115.660001

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

290

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26078453

http://www.w3.org/2001/XMLSchema#string

P921

P932

4528108

http://www.w3.org/2001/XMLSchema#string